$656.44 Million in Sales Expected for Endo International plc (NASDAQ:ENDP) This Quarter

Analysts expect that Endo International plc (NASDAQ:ENDPGet Rating) (TSE:ENL) will post $656.44 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Endo International’s earnings, with the lowest sales estimate coming in at $623.70 million and the highest estimate coming in at $693.00 million. Endo International reported sales of $713.83 million in the same quarter last year, which would suggest a negative year over year growth rate of 8%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Endo International will report full year sales of $2.59 billion for the current financial year, with estimates ranging from $2.50 billion to $2.72 billion. For the next year, analysts forecast that the business will post sales of $2.40 billion, with estimates ranging from $2.28 billion to $2.57 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Endo International.

Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) last announced its earnings results on Thursday, May 5th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.44 by $0.22. The firm had revenue of $652.26 million for the quarter, compared to the consensus estimate of $637.09 million. Endo International had a negative net margin of 24.82% and a negative return on equity of 82.00%. The business’s quarterly revenue was down 9.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 EPS.

Several analysts have issued reports on the stock. BMO Capital Markets decreased their price target on shares of Endo International from $8.00 to $4.00 in a research report on Thursday, March 3rd. Barclays lowered shares of Endo International from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $5.00 to $2.00 in a research report on Wednesday, March 2nd. Zacks Investment Research lowered shares of Endo International from a “hold” rating to a “strong sell” rating and set a $2.50 price target on the stock. in a research report on Wednesday, February 9th. Citigroup decreased their price target on shares of Endo International from $11.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, March 9th. Finally, Piper Sandler lowered shares of Endo International from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $3.00 to $1.00 in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Endo International has an average rating of “Hold” and a consensus target price of $4.50.

Several institutional investors have recently modified their holdings of ENDP. Parametric Portfolio Associates LLC boosted its position in shares of Endo International by 108.1% during the 4th quarter. Parametric Portfolio Associates LLC now owns 871,726 shares of the company’s stock valued at $3,278,000 after acquiring an additional 452,778 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Endo International by 11.0% during the 4th quarter. Geode Capital Management LLC now owns 4,280,507 shares of the company’s stock valued at $16,094,000 after purchasing an additional 425,177 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in Endo International by 161.7% during the 1st quarter. New York State Common Retirement Fund now owns 426,139 shares of the company’s stock valued at $984,000 after purchasing an additional 263,322 shares during the last quarter. Yousif Capital Management LLC bought a new position in Endo International during the 4th quarter valued at about $814,000. Finally, Jackson Creek Investment Advisors LLC bought a new position in Endo International during the 4th quarter valued at about $681,000. Institutional investors and hedge funds own 80.39% of the company’s stock.

Shares of ENDP opened at $1.42 on Monday. The company has a market capitalization of $331.81 million, a PE ratio of -0.46 and a beta of 1.07. Endo International has a one year low of $1.28 and a one year high of $7.07. The company’s fifty day moving average price is $2.33 and its 200 day moving average price is $3.60.

About Endo International (Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Featured Stories

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.